Table 6.

Impact of cardiac complications on transplant outcomes

Univariate analysis	OS, HR (95% CI)	P value	NRM, HR (95% CI)	P value
CEs
All events (time dependent)	1.98 (1.42-2.78)	<.001	3.73 (2.44-5.70)	<.001
CEs
ECE (time dependent)	1.72 (1.16-2.56)	<.001	5.72 (3.43-9.54)	<.001
LCE (time dependent)	2.51 (1.46-4.31)	<.001	5.53 (2.60-11.79)	<.001
GVHD prophylaxis
PTCY-based (vs others)	0.87 (0.71-1.06)	.188	1.14 (0.86-1.53)	.35

MVA	OS HR (95% CI)	P value	NRM HR (95% CI)	P value
CEs
All events (time dependent)	1.65 (1.16-2.34)	.005	2.88 (1.74-4.76)	<.001
GVHD prophylaxis
PTCY-based (vs others)	0.71 (0.53-0.96)	.026	0.81 (0.50-1.29)	.381
Patient age, y
>59 (vs younger)	1.16 (0.91-1.49)	.223	1.37 (0.91-2.02)	.133
HTN
Yes (vs no)	1.06 (0.81-1.39)	.653	1.29 (0.84-1.96)	.231
DLP
Yes (vs no)	1.38 (1.03-1.85)	.003	1.40 (0.89-2.21)	.139
HCT-CI
>3 (vs 0-3)	1.26 (0.96-1.65)	.086	1.32 (0.87-2.02)	.184
Disease status before allo-HCT
Refractory AML/active disease (vs complete remission)	2.50 (1.88-3.32)	<.001	N/A
Intensity
RIC (vs MAC)	1.13 (0.89-1.43)	.283	1.05 (0.73-1.51)	.772
Donor
Haploidentical (vs others)	1.28 (0.93-1.77)	.120	1.33 (0.79-2.25)	.267
Grade 3-4 aGVHD
Time-dependent variable	2.21 (1.67-2.92)	<.001	8.38 (5.98-11.75)	<.001

The impact of the 95 CEs in outcomes has been investigated in the entire cohort of patients included in the study. CE variable has been treated as a time-dependent variable. CEs occurring after disease relapse have not been accounted. Variables included in the multivariate model were selected based on results from supplemental Section 3 and if considered clinically relevant for the transplant success. The variable HCT-CI has been included instead of the variables prior cardiac toxicity, obesity, or diabetes mellitus.

HCT-CI, HCT–comorbidity index; RIC, reduced intensity conditioning.